In these studies, fetal malformations (primarily craniofacial defects such as cleft palate), limb malformations (ectrodactyly, micromelia, and amelia), rib/vertebral column anomalies, and/or reduced fetal weights were observed at dosages 20 mg/kg in mice (approximately 2 times the MRHD of topiramate in QSYMIA 15 mg/92 mg on a mg/m 2 basis), 20 mg/kg in rats (2 times the MRHD of QSYMIA based on estimated AUC), and 35 mg/kg in rabbits (2 times the MRHD based on estimated AUC)
Patients should maintain open communication with their healthcare providers about any new or worsening symptoms, including thirst, to ensure safe and effective treatment with tirzepatide
Of note, NMNH has been recently declared self-affirmed GRAS, which should accelerate its clinical development
Meanwhile, doubling down on lifestyle (diet, exercise, etc.) is something that costs little and still gives benefits, with or without medication
We analyzed 34 randomized clinical trials comparing: Continuous positive airway pressure (CPAP) GLP-1 receptor agonists No active intervention Here is what the evidence shows: CPAP remains the most effective therapy for reducing AHI GLP-1 receptor agonists produce clinically meaningful BMI and HbA1c reductions Blood pressure effects were inconsistent Respiratory and metabolic domains behave differently This is not a competition between CPAP and GLP-1 therapy
